A phase IIb trial of remogliflozin etabonate in patients with non-alcoholic steatohepatitis.

Trial Profile

A phase IIb trial of remogliflozin etabonate in patients with non-alcoholic steatohepatitis.

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2016

At a glance

  • Drugs Remogliflozin etabonate (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors Avolynt; BHV Pharma; Islet Sciences
  • Most Recent Events

    • 23 Apr 2015 According to a company media release, Islet Sciences plans to initiate this study in 2015.
    • 15 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top